Novel Molecular Glue Discovery Platform Unlocks Undruggable Cancer Targets
A scalable platform to discover molecular glue degraders has been developed, identifying the first metabolically activated glue. The approach expands protein degradation targets, enabling selective elimination of previously undruggable cancer-related proteins for therapeutic development. The post Novel Molecular Glue Discovery Platform Unlocks Undruggable Cancer Targets appeared first on GEN -…
Dana-Farber Cancer Institute researchers have developed a platform for discovering molecular glue degraders, which could expand the range of undruggable cancer targets that can be eliminated via targeted protein degradation. The platform, which fixes a subset of E3 ligases to magnetic beads and bathes them in cellular lysate and a library of drug compounds, enabled the discovery of the first metabolically activated molecular glue degrader, suggesting that molecular glues may be more context-dependent and tunable than previously thought.
The study, published in Nature, could help drive the significant expansion of molecular glue applications for the treatment of cancer and other diseases.
Brief written by urgent.news from GEN Biotechnology's own syndicated text. Machine-written — read the original for the full account.
We haven't written up this one. GEN Biotechnology has the full story — the link below goes straight to it.
